FDA OKs pivotal trial for AO (aqueous oxygen) heart attack system:
This article was originally published in Clinica
TherOx is pressing on with a US, phase II clinical study of its aqueous oxygen (AO) system for treating heart attack, after gaining the green light from the FDA. The device, which will be tested at 10 US centres, hyperoxygenates a patient's blood with AO and then delivers the treated blood to oxygen-deprived areas of the heart following heart attack. Early research suggests that the therapy could dramatically improve heart function following primary angioplasty in patients suffering a major heart attack, says the Irvine, California firm, which has already CE-marked the device for sale in Europe.